Who is sponsoring NCT03527693?

NCT03527693 is sponsored by Spotorno Foundation.

What drugs are being tested in NCT03527693?

Interventions in NCT03527693: Lipogems injection.

What condition does NCT03527693 study?

NCT03527693 studies Symptomatic Knee Osteoarthritis.

Is NCT03527693 still recruiting?

NCT03527693 is currently completed. Last updated 22 May 2018.

Last reviewed 2018-05-22 · How we verify

NCT03527693: LOOK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Micro-fragmented Adipose Tissue Injection Associated With Arthroscopic Procedures in Patients With Knee Osteoarthritis

Completed Last updated 22 May 2018

What this trial tests

trial testing Lipogems injection in Symptomatic Knee Osteoarthritis in 38 participants. Completed in 31 December 2016.

Timeline

1 January 2015

Primary endpoint
31 December 2015

31 December 2016

Quick facts

Lead sponsor	Spotorno Foundation
Status	Completed
Study type	OBSERVATIONAL
Enrollment	38
Start date	1 January 2015
Primary completion	31 December 2015
Estimated completion	31 December 2016

Drugs / interventions tested

Lipogems injection

Conditions studied

Symptomatic Knee Osteoarthritis — all drugs for Symptomatic Knee Osteoarthritis →

Sponsor

Spotorno Foundation

Who can join

Eligibility, any sex, with Symptomatic Knee Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study aims to evaluate the effects of a single intra-articular injection of micro-fragmented adipose tissue obtained with the Lipogems® system in patients affected by knee chondropathy. End-points were determined by evaluating the patients in terms of improvement in symptoms, functional recovery and radiographic appearance compared to baseline.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Micro-fragmented adipose tissue injection associated with arthroscopic procedures in patients with symptomatic knee osteoarthritis.
Cattaneo G, De Caro A, Napoli F, Chiapale D, et al · · 2018 · cited 58× · PMID 29848328 · DOI 10.1186/s12891-018-2105-8
The Current Status of Clinical Trials on Biologics for Cartilage Repair and Osteoarthritis Treatment: An Analysis of ClinicalTrials.gov Data.
Zhang Z, Schon L. · · 2022 · cited 21× · PMID 35546280 · DOI 10.1177/19476035221093065

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03527693 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spotorno Foundation
Last refreshed: 22 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03527693.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing